{"transactions":[{"id":672115,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-09-01T01:59:36.000Z","date":"2026-08-28","kind":"sale","planned":true,"acquired":false,"shares":700,"price":60.9766,"value":42683.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $60.81 to $61.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares beneficially owned following the reported transactions reflects an upward adjustment of one share from the reporting person's previous Form 4 filed on March 13, 2026, based on updated tax withholding calculations for the transactions described on the previously filed Form 4."}],"balance_after":2,"source":{"system":"sec-edgar","filing":"0001193125-26-377309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526377309/ownership.xml","form_type":"4"}},{"id":672114,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-09-01T01:59:36.000Z","date":"2026-08-28","kind":"sale","planned":true,"acquired":false,"shares":6368,"price":60.1673,"value":383145.3664,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $59.79 to $60.68, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":702,"source":{"system":"sec-edgar","filing":"0001193125-26-377309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526377309/ownership.xml","form_type":"4"}},{"id":844080,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Share Units","published_at":"2026-03-14T00:16:56.000Z","date":"2026-03-12","kind":"exercise","planned":true,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":11250,"derivative":{"underlying":"Common Shares","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001193125-26-106727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526106727/ownership.xml","form_type":"4"}},{"id":844079,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-03-14T00:16:56.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":1410,"price":55.225,"value":77867.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of RSUs granted on March 12, 2025."}],"balance_after":7069,"source":{"system":"sec-edgar","filing":"0001193125-26-106727","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526106727/ownership.xml","form_type":"4"}},{"id":844078,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-03-14T00:16:56.000Z","date":"2026-03-12","kind":"exercise","planned":true,"acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":8479,"source":{"system":"sec-edgar","filing":"0001193125-26-106727","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526106727/ownership.xml","form_type":"4"}},{"id":848990,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance Share Units","published_at":"2026-03-11T23:21:20.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001193125-26-102669","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526102669/ownership.xml","form_type":"4"}},{"id":848989,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance Share Units","published_at":"2026-03-11T23:21:20.000Z","date":"2026-03-09","kind":"grant","planned":true,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":7500,"derivative":{"underlying":"Common Shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001193125-26-102669","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526102669/ownership.xml","form_type":"4"}},{"id":848988,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-03-11T23:21:20.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":2771,"price":60.108,"value":166559.268,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of PSUs granted on March 11, 2024."}],"balance_after":4729,"source":{"system":"sec-edgar","filing":"0001193125-26-102669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526102669/ownership.xml","form_type":"4"}},{"id":848987,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-03-11T23:21:20.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001193125-26-102669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526102669/ownership.xml","form_type":"4"}},{"id":942295,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Share Units","published_at":"2026-01-09T23:54:57.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."}],"balance_after":20000,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-009238","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526009238/ownership.xml","form_type":"4"}},{"id":942294,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2026-01-09T23:54:57.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":100000,"derivative":{"exercise_price":42.15,"expiration_date":"2036-01-08","underlying":"Common Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-009238","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000119312526009238/ownership.xml","form_type":"4"}},{"id":1207963,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Share Units","published_at":"2025-03-13T23:31:01.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":15000,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-25-039021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000095017025039021/ownership.xml","form_type":"4"}},{"id":1207962,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2025-03-13T23:31:01.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on March 12, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":80000,"derivative":{"exercise_price":35.48,"expiration_date":"2035-03-11","underlying":"Common Shares","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-25-039021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000095017025039021/ownership.xml","form_type":"4"}},{"id":1581678,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-12T22:38:34.000Z","date":"2024-03-11","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":100000,"derivative":{"exercise_price":44.37,"expiration_date":"2034-03-10","underlying":"Common Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-24-030239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000095017024030239/ownership.xml","form_type":"4"}},{"id":1939272,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2023-03-24T23:18:57.000Z","date":"2023-03-24","kind":"sale","planned":false,"acquired":false,"shares":700,"price":35.01,"value":24507.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-021136","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000120919123021136/doc4.xml","form_type":"4"}},{"id":1954567,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-14T20:32:22.000Z","date":"2023-03-10","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":120000,"derivative":{"exercise_price":34.18,"expiration_date":"2033-03-09","underlying":"Common Shares","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001209191-23-018476","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000120919123018476/doc4.xml","form_type":"4"}},{"id":2335786,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-14T20:13:13.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":125000,"derivative":{"exercise_price":30.01,"expiration_date":"2032-03-09","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-22-018449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000120919122018449/doc4.xml","form_type":"4"}},{"id":2428941,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2022-01-21T22:04:38.000Z","date":"2022-01-21","kind":"purchase","acquired":true,"shares":700,"price":28.81,"value":20167.0,"ownership":{"direct":true},"balance_after":700,"source":{"system":"sec-edgar","filing":"0001209191-22-004460","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000120919122004460/doc4.xml","form_type":"4"}},{"id":2591086,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":18438,"kind":"person","name":"KENNEY CHRISTOPHER JOHN","position":1,"cik":"0001880129","reported_name":"KENNEY CHRISTOPHER JOHN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-25T20:12:29.000Z","date":"2021-08-23","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on the one year anniversary of the grant date, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on\nthe last day of each month."}],"balance_after":150000,"derivative":{"exercise_price":16.64,"expiration_date":"2031-08-22","underlying":"Common Shares","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-21-053304","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880129/000120919121053304/doc4.xml","form_type":"4"}}]}